Are Bundled Radiopharmaceutical Payments Hurting Nuclear Medicine Access and Innovation?

Read the full article now!

For years the bundling of radiopharmaceuticals with the technical portion for one payment to the provider has been a bone of contention. Bundling the radiopharmaceutical and treating it as a consumable rather than a drug, means that the provider can lose money on every scan done with necessary high ticket radiopharmaceuticals. The question is whether this approach to Medicare cost-cutting is hurting the use of nuclear medicine and limiting the development of new tracers? In the end, Medicare may save a few dollars but, the question as to the quality of patient care decisions driven by a need to at least break even is still open.

Read the full article in this month’s issue of HealthCare Business News